The key to the valuation is what type of deal they can strike up...

The key to the valuation is what type of deal they can strike up with the pharma's.

Also reliant on how the human trials go, refer to article below.

Taking a Shot

An Australian company has licensed rights to nee-
dle-free injection technology from MIT. Norwood
Abbey of Melbourne received an exclusive world-
wide license for the technology. The license covers
10 patent families, including one issued U.S. patent
and 50 patent applications. MIT will earn royalties
from any products that are commercialized.

The needle-free injector is a little larger than an
electric toothbrush. It contains a small fiber of a
conductive polymer that contracts very rapidly
when voltage is applied. The fiber exerts pressure
on a small quantity of the drug to be injected, forc-
ing it out at such a high speed that it shoots through
the skin.

Prior to injection, a miniature probe pokes
at the skin to determine how stiff it is and adjusts
the pressure accordingly.

The system was invented by Ian Hunter, Hatso-
poulos Professor of Mechanical Engineering and
head of MIT’s Bioinstrumentation Laboratory.

Abbey and has been working with the company on
developing the technology. The lab has performed
live animal studies on the device for veterinary
applications and recently conducted preliminary
human trials.